Eli Lilly said Wednesday that its experimental drug solanezumab failed to improve cognition of patients with mild Alzheimer's disease in a large phase III clinical trial.

If you liked this article you might like

Apple, Starbucks, Cisco: Doug Kass' Views
Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield
Lilly's Setback Raises Stakes for Other Alzheimer Drug Companies
Jim Cramer -- Eli Lilly's Alzheimer Drug Failure Is a Major Disaster